미국의 항체약물접합체(ADC) 시장 규모, 점유율, 동향 분석 보고서 : 용도별, 기술별, 제품별, 타겟별, 부문별 예측(2025-2030년)

U.S. Antibody Drug Conjugates Market Summary

The U.S. antibody drug conjugates market size was valued at USD 7.15 billion in 2024 and is projected to reach USD 10.60 billion by 2030, growing at a CAGR of 4.9% from 2025 to 2030. This can be attributed to the increasing incidence of cancer cases and increased demand for low-toxicity & effective drugs.

Also, pharmaceutical and biotech companies are investing heavily in researching and developing antibody drug conjugates (ADCs), propelling market growth. The growing number of cancer cases in the U.S. significantly fuels demand for targeted therapies like ADCs. According to the American Cancer Society Inc., in 2024, over 2 million new cancer cases were detected in the U.S. The number of cancer cases is rising due to various factors such as aging populations, lifestyle changes, and improved diagnostic capabilities. ADCs offer a highly focused approach that delivers cytotoxic drugs straight to cancer cells, reducing damage to healthy tissues. This accuracy makes ADCs preferred to traditional chemotherapy, especially for challenging cancers.

The rising funding is accelerating the development of ADCs across a wider range of indications beyond oncology. For instance, in March 2025, Callio Therapeutics, a biotechnology firm dedicated to multi-payload ADCs aimed at cancer treatment, declared its launch after securing USD 187 million in Series A funding led by Frazier Life Sciences. Callio intends to use the funds to progress clinical proof-of-concept for its HER2-targeted dual-payload ADC.

The rising technological innovations in antibody manufacturing, linker stability, and cytotoxic payloads have led to the development of effective and safer ADCs. In September 2024, Merck launched the Mobius ADC Reactor, a single-use reactor designed to manufacture ADCs that precisely target and eliminate tumor cells while leaving healthy tissue unharmed.

Mergers and acquisitions (M&A) are moderate, with prominent pharmaceutical companies focusing on acquiring companies with expertise in ADC technologies to improve their oncology portfolios. For instance, in March 2024, Johnson & Johnson Services, Inc. acquired Ambrx Biopharma, Inc. It has a proprietary synthetic biology technology platform to develop and design next-generation ADC. This is expected to deliver differentiated solid tumor treatment to improve the lives of patients'.

U.S. Antibody Drug Conjugates Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. antibody drug conjugates market report based on application, product, target, and technology:

• Application (Revenue, USD Million, 2018 - 2030)
• Blood Cancer
  • Leukemia
  • Lymphoma
  • Multiple Myeloma
• Breast Cancer
• Urothelial Cancer & Bladder Cancer
• Other Cancer
• Product Outlook (Revenue, USD Million, 2018 - 2030)
• Kadcyla
• Enhertu
• Adcetris
• Padcev
• Trodelvy
• Polivy
• Others
• Target Outlook (Revenue, USD Million, 2018 - 2030)
• HER2
• CD22
• CD30
• Others
• Technology Outlook (Revenue, USD Million, 2018 - 2030)
• Type
  • Cleavable Linker
  • Non-cleavable Linker
  • Linkerless
• Linker Technology Type
  • VC
  • Sulfo-SPDB
  • VA
  • Hydrazone
  • Others
• Payload Technology
  • MMAE
  • MMAF
  • DM4
  • Camptothecin
  • Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1. Purchased Database
  • 1.3.2. GVR's Internal Database
  • 1.3.3. Secondary Sources & Third-Party Perspectives
  • 1.3.4. Primary Research
• 1.4. Information Analysis
  • 1.4.1. Data Analysis Models
• 1.5. Market Formulation & Data Visualization
• 1.6. Data Validation & Publishing

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Antibody Drug Conjugates Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related Market Outlook
• 3.2. Industry Value Chain Analysis
• 3.3. Regulatory Framework
• 3.4. Market Dynamics
  • 3.4.1. Market Driver Analysis
  • 3.4.2. Market Restraint Analysis
  • 3.4.3. Industry Challenges
  • 3.4.4. Industry Opportunities
• 3.5. Industry Analysis Tools
  • 3.5.1. Porter's Five Forces Analysis
  • 3.5.2. Macro-environmental Analysis

Chapter 4. U.S. Antibody Drug Conjugates Market: Application Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Antibody Drug Conjugates Market: Application Movement Analysis & Market Share, 2024 & 2030
• 4.3. Blood Cancer
  • 4.3.1. Blood Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3.2. Leukemia
    • 4.3.2.1. Leukemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3.3. Lymphoma
    • 4.3.3.1. Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3.4. Multiple Myeloma
    • 4.3.4.1. Multiple Myeloma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Breast Cancer
  • 4.4.1. Breast Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Urothelial Cancer & Bladder Cancer
  • 4.5.1. Urothelial Cancer & Bladder Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Other Cancer
  • 4.6.1. Urothelial Cancer & Bladder Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Antibody Drug Conjugates Market: Product Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Antibody Drug Conjugates Market: Product Movement Analysis & Market Share, 2024 & 2030
• 5.3. Kadcyla
  • 5.3.1. Kadcyla Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Enhertu
  • 5.4.1. Enhertu Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Adcetris
  • 5.5.1. Adcetris Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Padcev
  • 5.6.1. Padcev Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Trodelvy
  • 5.7.1. Trodelvy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. Polivy
  • 5.8.1. Polivy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.9. Others
  • 5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Antibody Drug Conjugates Market: Target Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Antibody Drug Conjugates Market: Target Movement Analysis & Market Share, 2024 & 2030
• 6.3. HER2
  • 6.3.1. HER2 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. CD22
  • 6.4.1. CD22 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. CD30
  • 6.5.1. CD30 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. U.S. Antibody Drug Conjugates Market: Technology Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. U.S. Antibody Drug Conjugates Market: Technology Movement Analysis & Market Share, 2024 & 2030
• 7.3. Type
  • 7.3.1. Type Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.2. Cleavable Linker
    • 7.3.2.1. Cleavable Linker Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.3. Non-cleavable Linker
    • 7.3.3.1. Non-cleavable Linker Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.4. Linkerless
    • 7.3.4.1. Linkerless Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Linker Technology Type
  • 7.4.1. Linker Technology Type Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. VC
    • 7.4.2.1. VC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Sulfo-SPDB
    • 7.4.3.1. Sulfo-SPDB Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. VA
    • 7.4.4.1. VA Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.5. Hydrazone
    • 7.4.5.1. Hydrazone Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.6. Others
    • 7.4.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Payload Technology
  • 7.5.1. Payload Technology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. MMAE
    • 7.5.2.1. MMAE Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. MMAF
    • 7.5.3.1. MMAF Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. DM4
    • 7.5.4.1. DM4 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Camptothecin
    • 7.5.5.1. Camptothecin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Others
    • 7.5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. U.S. Antibody Drug Conjugates Market - Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Heat Map
• 8.4. Position Analysis, 2024
• 8.5. Strategy Mapping
  • 8.5.1. Expansion
  • 8.5.2. Mergers & Acquisition
  • 8.5.3. Partnerships & Collaborations
  • 8.5.4. New Product Launches
  • 8.5.5. Research and Development
• 8.6. Company Profiles
  • 8.6.1. Seagen, Inc.
    • 8.6.1.1. Participant's overview
    • 8.6.1.2. Financial performance
    • 8.6.1.3. Product benchmarking
    • 8.6.1.4. Recent developments
  • 8.6.2. Takeda Pharmaceutical Company Ltd.
    • 8.6.2.1. Participant's overview
    • 8.6.2.2. Financial performance
    • 8.6.2.3. Product benchmarking
    • 8.6.2.4. Recent developments
  • 8.6.3. AstraZeneca
    • 8.6.3.1. Participant's overview
    • 8.6.3.2. Financial performance
    • 8.6.3.3. Product benchmarking
    • 8.6.3.4. Recent developments
  • 8.6.4. F. Hoffmann-La Roche Ltd.
    • 8.6.4.1. Participant's overview
    • 8.6.4.2. Financial performance
    • 8.6.4.3. Product benchmarking
    • 8.6.4.4. Recent developments
  • 8.6.5. Pfizer, Inc.
    • 8.6.5.1. Participant's overview
    • 8.6.5.2. Financial performance
    • 8.6.5.3. Product benchmarking
    • 8.6.5.4. Recent developments
  • 8.6.6. Gilead Sciences, Inc.
    • 8.6.6.1. Participant's overview
    • 8.6.6.2. Financial performance
    • 8.6.6.3. Product benchmarking
    • 8.6.6.4. Recent developments
  • 8.6.7. Daiichi Sankyo Company Ltd.
    • 8.6.7.1. Participant's overview
    • 8.6.7.2. Financial performance
    • 8.6.7.3. Product benchmarking
    • 8.6.7.4. Recent developments
  • 8.6.8. GlaxoSmithKline Plc
    • 8.6.8.1. Participant's overview
    • 8.6.8.2. Financial performance
    • 8.6.8.3. Product benchmarking
    • 8.6.8.4. Recent developments
  • 8.6.9. Astellas Pharma, Inc.
    • 8.6.9.1. Participant's overview
    • 8.6.9.2. Financial performance
    • 8.6.9.3. Product benchmarking
    • 8.6.9.4. Recent developments
  • 8.6.10. ADC Therapeutics SA
    • 8.6.10.1. Participant's overview
    • 8.6.10.2. Financial performance
    • 8.6.10.3. Product benchmarking
    • 8.6.10.4. Recent developments